Key result
Tirzepatide improved cardiometabolic risk factors in proportion to weight loss, with the steepest effect between <5% and <20% weight reduction and lipid improvements primarily after >10% reduction.
Why the study?
Does the degree of tirzepatide-induced weight reduction correlate with improvements in cardiometabolic risk factors in adults with obesity or overweight?
RCT (n=1,605)
double-blind
randomized
Yes
Does the degree of tirzepatide-induced weight reduction correlate with improvements in cardiometabolic risk factors in adults with obesity or overweight?
Tirzepatide-induced weight loss dose-dependently improves cardiometabolic risk factors, though significant lipid improvements generally require greater than 10% weight reduction.
Answers are grounded in this paper and cite their sources.
Greater weight loss with tirzepatide linked to larger cardiometabolic gains, varying by factor; extends SURMOUNT-1 dose-response data but requires confirmation.
BACKGROUND: Tirzepatide reduced weight and improved cardiometabolic risk factors for participants in the SURMOUNT-1 trial. The changes in cardiometabolic risk factors by degree of tirzepatide-induced weight reduction across a wide spectrum of weight loss have not been reported. OBJECTIVE: To determine changes in cardiometabolic risk factors by weight reduction. DESIGN: Post hoc analysis of the phase 3, randomized, double-blind, SURMOUNT-1 trial (ClinicalTrials.gov: NCT04184622). SETTING: 119 sites in 9 countries. PARTICIPANTS: = 1605) with obesity, or overweight with weight-related complications (excluding diabetes), randomly assigned to tirzepatide treatment groups. INTERVENTION: Once-weekly tirzepatide, 5, 10, or 15 mg. MEASUREMENTS: Changes from baseline to week 72 in cardiometabolic risk factors by weight reduction. RESULTS: were observed even with modest weight reduction, with the steepest effect occurring between less than 5% and less than 20% weight reduction. Improvements in levels of triglycerides, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein cholesterol, and non-HDL cholesterol were primarily observed only after weight reductions greater than 10%. Results were consistent after adjustment for baseline differences. LIMITATIONS: The analysis was post hoc and should be regarded as hypothesis-generating. Duration and sample size precluded evaluation of cardiovascular outcomes. CONCLUSION: In SURMOUNT-1, tirzepatide-associated improvements in cardiometabolic risk factors positively related to the degree of weight reduction, but the pattern varied depending on outcome measure. PRIMARY FUNDING SOURCE: Eli Lilly and Company.
No takes yet. Share an insight, caveat, or question.
Linetzky et al. (2025) conducted an RCT in Obesity, or overweight with weight-related complications (excluding diabetes) (n=1,605). Tirzepatide was evaluated on Changes from baseline to week 72 in cardiometabolic risk factors by weight reduction. Tirzepatide improved cardiometabolic risk factors in proportion to weight loss, with the steepest effect between <5% and <20% weight reduction and lipid improvements primarily after >10% reduction.
Synapse has enriched 10 related papers. Consider them for comparative context: